Natural product synthesis aims to prepare a complex target molecule such that the product is analytically identical to the naturally occurring compound, termed a natural product. It is used for ...

See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to ...

Alyftrek combines vanzacaftor, tezacaftor and deutivacaftor and is the fifth cystic fibrosis transmembrane conductance regulator (CFTR) modulator from Vertex. The FDA approval covers patients who ...

ALYFTREK ™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head ...

Like Trikafta, the newly approved product is a triple-combination therapy intended for use in people with at least one F508del mutation or another mutation in the CFTR gene that is responsive to the ...

State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates South China University of Technology, Guangzhou 510640, China ...

The U.S. Food and Drug Administration (FDA) today approved the expansion of Trikafta (elexacaftor/tezacaftor/ivacaftor) to people with cystic fibrosis ages 2 and ...

With this approval, 94 additional non-F508del CFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to ...

Eligible patients must have at least one mutation in F508del or another responsive mutation in the CFTR gene. Of note, the CFTR modulator carries a boxed warning over the risk of drug-induced ...

The process of drug discovery and development is inherently complex, resource-intensive, and multidisciplinary. Organic synthesis and catalysis play key roles in transforming this process by enabling ...